Citations

Showing 10 of 108104 citations.

Functional Analysis and Fine Mapping of the 9p22.2 Ovarian Cancer Susceptibility Locus
Buckley, Melissa A., Woods, Nicholas T. , Mendoza-Fandiño, Gustavo, Lawrenson, Kate , Hazelett, Dennis J. , Najafabadi, Hamed S. , Gjyshi, Anxhela, Carvalho, Renato S. , Lyra, Paulo C. , Shen, Howard C., Yang, Ally , Earp, Madalene A. , Yoder, Sean J., Chenevix‐Trench, Georgia , Ramus, Susan J. , Phelan, Catherine M., Coetzee, Gerhard A., Hughes, Timothy R. , Sellers, Thomas A. , Goode, Ellen L. , Gayther, Simon A. , Monteiro, Álvaro N.A. , Lu, Karen H. , Goodman, Marc T. , Lissowska, Jolanta , Jakubowska, Anna , Dörk, Thilo , Matsuo, Keitaro , Menon, Usha , Terry, Kathryn L. , Tworoger, Shelley S. , Ekici, Arif B. , Chen, Y. Ann , Eccles, Diana , Teo, Soo‐Hwang , Hein, Alexander , Hillemanns, Peter , Lambrechts, Diether , Jensen, Allan , Brooks‐Wilson, Angela , Sieh, Weiva , Dansonka‐Mieszkowska, Agnieszka , Liang, Dong , Woo, Yin Ling , McNeish, Iain A. , Lambrechts, Diether , Lawrenson, Kate , Hazelett, Dennis J , Najafabadi, Hamed S , Coetzee, Simon G , Ramus, Susan J , Noushmehr, Houtan , Dörk, Thilo , Lambrechts, Diether , McNeish, Iain A , Teo, Soo H , Tworoger, Shelley S , Hein, Alexander , Hillemanns, Peter , Jensen, Allan , Eccles, Diana , Menon, Usha , Monteiro, Alvaro N , Lissowska, Jolanta , Brooks-Wilson, Angela R , Matsuo, Keitaro , Jakubowska, Anna , Lambrechts, Diether , Sieh, Weiva , Ekici, Arif B , Chenevix-Trench, Georgia , Goodman, Marc T , Tyrer, Jonathan P. , Coetzee, Simon G. , Yoder, Sean , Risch, Harvey A. , Noushmehr, Houtan , Pharoah, Paul D.P. , Morais Lyra, Paulo Cilas

Mayo Clinic

Cancer Research | November 28, 2018 | Volume: 79 | Issue: 3 | Pages: 467-481

10.1158/0008-5472.can-17-3864 | PMID 30487138 Get It

Abstract Genome-wide association studies have identified 40 ovarian cancer risk loci. However, the mechanisms underlying these associations remain elusive. In this study, we conducted a two-pronged approach to identify candidate causal SNPs and assess underlying biological mechanisms at chromosome 9p22.2, the first and most statistically significant associated locus for ovarian cancer susceptibility. Three transcriptional regulatory elements with allele-specific effects and a scaffold/matrix attachment region were characterized and, through physical DNA interactions, BNC2 was established as the most likely target gene. We determined the consensus binding sequence for BNC2 in vitro, verified its enrichment in BNC2 ChIP-seq regions, and validated a set of its downstream target genes. Fine-mapping by dense regional genotyping in over 15,000 ovarian cancer cases and 30,000 controls identified SNPs in the scaffold/matrix attachment region as among the most likely causal variants. This study reveals a comprehensive regulatory landscape at 9p22.2 and proposes a likely mechanism of susceptibility to ovarian cancer. Significance: Mapping the 9p22.2 ovarian cancer risk locus identifies BNC2 as an ovarian cancer risk gene. See related commentary by Choi and Brown, p. 439
Improvements in Thigh Strength Symmetry Are Modestly Correlated With Changes in Self-Reported Function After Anterior Cruciate Ligament Reconstruction
Pottkotter, Kristy , Stasi, Stephanie L. Di, Schmitt, Laura C. , Magnussen, Robert A. , Paterno, Mark V. , Flanigan, David C. , Kaeding, Christopher C. , Hewett, Timothy E.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | November 28, 2018 | Volume: 6 | Issue: 11 | Pages: No page available

10.1177/2325967118807459 | PMID 30534573 Get It

Background: The association between quadriceps strength and functional outcomes after anterior cruciate ligament reconstruction (ACLR) is a focus of current research, while evaluations of hamstring strength are limited, despite the frequent use of hamstring autografts. Purpose/Hypothesis: The purpose of this study was to determine the relationship between changes in quadriceps and hamstring strength symmetry and self-reported outcomes before ACLR and at 12 and 24 weeks after surgery. We hypothesized that improvements in quadriceps and hamstring strength symmetry would be correlated with improvements in self-reported outcome measures within the first 6 months after ACLR. Study Design: Cohort study; Level of evidence, 2. Methods: Thirty patients who underwent ACLR with a hamstring autograft were enrolled. Quadriceps and hamstring strength and Knee injury and Osteoarthritis Outcome Score (KOOS) values were assessed before and at 12 and 24 weeks after ACLR; limb symmetry indexes for strength were calculated at each time point. The Friedman and Wilcoxon signed-rank tests were used to analyze changes in KOOS values over time. Spearman rank-order correlations were used to test the relationship between changes in strength and KOOS values between each time point. Results: Hamstring and quadriceps limb symmetry significantly increased with time ( P ≤ .03). Fair correlations were observed between changes in the hamstring index and changes in the KOOS Symptoms subscore from before surgery to 12 weeks postoperatively ( r = 0.48; P ≤ .05). Changes in the quadriceps index (QI) were moderately correlated with changes in the KOOS Sport/Recreation subscore ( r = 0.60; P = .001), and fair correlations were seen between the QI and the KOOS Quality of Life subscore ( r = 0.39; P ≤ .04) from preoperatively to 12 weeks after surgery. Moderate correlations were seen between the QI and the KOOS Sport/Recreation subscore ( r = 0.57; P = .005) from 12 to 24 weeks after surgery. Conclusion: Improvements in quadriceps and hamstring strength symmetry were modestly associated with improvements in athletes’ perceived function in the first 6 months after ACLR. Specifically, improvements in hamstring symmetry were associated with improvements in knee symptoms within the first 12 weeks postoperatively, while improvements in quadriceps symmetry were associated with improvements in self-reported sport function throughout the first 6 months after ACLR. The restoration of strength symmetry within the first 6 months may be a critical component of rehabilitation aimed at maximizing function after ACLR. Further investigation is warranted to comprehensively evaluate whether the timing of strength gains predicts future function, including those who successfully return to their preinjury activity level after ACLR.
Bioactive Signaling in Next-Generation Pharmacotherapies for Heart Failure
Oatmen, Kelsie E., Zile, Michael R. , Burnett, John C. , Spinale, Francis G. , Zile, Michael R

Mayo Clinic

JAMA Cardiology | November 28, 2018 | Volume: 3 | Issue: 12 | Pages: 1232

10.1001/jamacardio.2018.3789 | PMID 30484834 Get It

The Timing Hypothesis: Hormone Therapy for Treating Symptomatic Women During Menopause and Its Relationship to Cardiovascular Disease
Mehta, Jaya , Chester, Rebecca , Kling, Juliana M. , Mehta, Jaya M, Chester, Rebecca C, Kling, Juliana M

Mayo Clinic

Journal of Women's Health | November 28, 2018 | Volume: 28 | Issue: 5 | Pages: 705-711

10.1089/jwh.2018.7201 | PMID 30484736 Get It

The risks and benefits of menopausal hormonal therapy (HT) have been evaluated extensively over the past three decades. While the efficacy of HT for management of menopausal symptoms, including vasomotor symptoms and vaginal dryness is well established, its relationship to cardiovascular outcomes is complex. The timing hypothesis, which posits that the cardiovascular effects of HT depend on the timing of initiation of HT in relation to menopause, has helped shape our understanding of the cardiovascular outcomes related to HT. Based on results from female monkey studies, the timing hypothesis provides a framework to explain discrepancies in results between multiple observation studies and the Women's Health Initiative (WHI) hormone therapy trials. The WHI trials closed early in 2002 in part because of increased cardiovascular events seen in women on treatment. Subanalysis of the WHI results by age group, and more recent randomized control studies, including the Kronos Early Estrogen and Prevention Study (KEEPS) and Early Versus Late Intervention Trial (ELITE), demonstrate that the risk of adverse cardiovascular events for HT are low for women <60 years of age or within 10 year from menopause. Although current data does not support using HT for primary prevention of cardiovascular disease, it does suggest that HT can be safely used to treat symptoms in appropriately selected women close to menopause.
What about Disposition?
Jacoby, Jacob, Berning, Carol Kohn, Dietvorst, Thomas F.

Mayo Clinic

Journal of Marketing | November 28, 2018 | Volume: 41 | Issue: 2 | Pages: 22-28

10.1177/002224297704100212 Get It

What do consumers do with products once they have outlived their usefulness, and how does this relate to the purchase of replacement products?
European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium
Luster, Markus , Aktolun, Cumali , Amendoeira, Isabel, Bible, Keith C. , Duntas, Leonidas H. , Handkiewicz-Junak, Daria , Hoffmann, Martha, Jarząb, Barbara , Musholt, Thomas J. , Newbold, Kate, Nixon, Iain J. , Sobrinho‐Simões, Manuel , Tuttle, R. Michael , Verburg, Frederik A. , Wartofsky, Leonard , Führer, Dagmar, Barczyński, Marcin , Elisei, Rossella , Leenhardt, Laurence , Smit, Johannes W. A. , Sosa, Julie Ann

Mayo Clinic

Thyroid | November 28, 2018 | Volume: 29 | Issue: 1 | Pages: 7-26

10.1089/thy.2017.0129 | PMID 30484394 Get It

PSB 2019 Workshop on Text Mining and Visualization for Precision Medicine
Lu, Zhiyong , Leaman, Robert , Du, Jingcheng , Fluck, Juliane , Holmes, John, Ouyang, Zhengqing , Schaaf, Sebastian , Zhang, Yuping , Gonzalez‐Hernandez, Graciela , Weissenbacher, Davy , Boland, Mary Regina , Chen, Yong , Greene, Casey S. , Kashyap, Aditya, Nielsen, Rikke Linnemann , Taroni, Jaclyn , Tao, Cui , Liu, Hongfang

Mayo Clinic

Biocomputing 2019 | November 28, 2018 | Volume: No volume available | Issue: No issue available | Pages: 449-454

10.1142/9789813279827_0042 Get It

Detecting potential pleiotropy across cardiovascular and neurological diseases using univariate, bivariate, and multivariate methods on 43,870 individuals from the eMERGE network
Zhang, Xinyuan , Veturi, Yogasudha , Bone, William P. , Lucas, Anastasia, Hebbring, Scott J. , Stanaway, Ian B. , Jarvik, Gail P. , Crosslin, David R. , Larson, Eric B. , Sleiman, Patrick , Fasel, David , Wei, Wei‐Qi, Schaid, Daniel J. , Ritchie, Marylyn D. , Jarvik, Gail P , Wei, Wei-Qi , Verma, Shefali S. , Verma, Anurag , Denny, Joshua C. , Rasmussen‐Torvik, Laura J. , Pendergrass, Sarah A. , Smoller, Jordan W. , Håkonarson, Håkon , Weng, Chunhua , Kullo, Iftikhar J. , Chung, Wendy K.

Mayo Clinic

Biocomputing 2019 | November 28, 2018 | Volume: No volume available | Issue: No issue available | Pages: 272-283

10.1142/9789813279827_0025 Get It

No free rides: management of toxicities of novel immunotherapies in ALL, including financial
Jain, Tania , Litzow, Mark R. , Jain, Tania

Mayo Clinic

Blood Advances | November 27, 2018 | Volume: 2 | Issue: 22 | Pages: 3393-3403

10.1182/bloodadvances.2018020198 | PMID 30482769 Get It

Abstract Therapeutic options for acute lymphoblastic leukemia, especially in the relapsed/refractory setting, have expanded significantly in recent times. However, this comes at the cost of toxicities: medical as well as financial. We highlight some of the unique toxicities associated with the novel agents to apprise our readers about what to expect, how to recognize them, and how to manage these toxicities. One of the toxicities seen with inotuzumab, a CD22 antibody drug conjugate, is sinusoidal obstruction syndrome, which can be fatal in &gt;80% of patients if associated with multiorgan failure. Blinatumomab, a monoclonal antibody targeting CD19, is associated with cytokine release syndrome (CRS) and neurotoxicity, both of which require prompt recognition and management primarily with corticosteroids. CRS and neurotoxicity are more common and more severe with chimeric antigen receptor T-cell therapy (CAR-T). The fact that CAR-T cannot be discontinued on demand adds a layer of complexity to the management of related toxicities of this therapy. Tocilizumab, an interleukin-6 receptor blocker, is used to treat severe CRS from CAR-T, whereas corticosteroids remain the mainstay for neurotoxicity management. Although effective, these drugs carry a high price tag, and we review the available data on cost-effectiveness of these agents, keeping in mind that median follow-up on most of these studies is limited and that long-term data on durability of response remain to be seen.
Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts
Link, Brian K. , Ghesquières, Hervé , Nicolas, Émmanuelle , Thompson, Carrie A. , Traverse‐Glehen, Alexandra , Allmer, Cristine, Ansell, Stephen M. , Salles, Gilles , Link, Brian K , Salles, Gilles A , Sarkozy, Clémentine , Maurer, Matthew J. , Nicolas, Emmanuelle, Feldman, Andrew L. , Slager, Susan L. , Habermann, Thomas M. , Bachy, Emmanuel , Cerhan, James R.

Mayo Clinic

Journal of Clinical Oncology | November 27, 2018 | Volume: 37 | Issue: 2 | Pages: 144-152

10.1200/jco.18.00400 | PMID 30481079 Get It

Purpose Although the life expectancy of patients with follicular lymphoma (FL) has increased, little is known of their causes of death (CODs) in the rituximab era. Patients and Methods We pooled two cohorts of newly diagnosed patients with FL grade 1-3A. Patients were enrolled between 2001 and 2013 in two French referral institutions (N = 734; median follow-up 89 months) and 2002 and 2012 in the University of Iowa and Mayo Clinic Specialized Program of Research Excellence (SPORE; N = 920; median follow-up 84 months). COD was classified as being a result of lymphoma, other malignancy, treatment related, or all other causes. Results Ten-year overall survival was comparable in the French (80%) and US (77%) cohorts. We were able to classify COD in 248 (88%) of 283 decedents. In the overall cohort, lymphoma was the most common COD, with a cumulative incidence of 10.3% at 10 years, followed by treatment-related mortality (3.0%), other malignancy (2.9%), other causes (2.2%), and unknown (3.0%). The 10-year cumulative incidence of death as a result of lymphoma or treatment was higher than death as a result of all other causes for each age group (including patients ≥ 70 years of age at diagnosis [25.4% v 16.6%]) Follicular Lymphoma International Prognostic Index score 3 to 5 (27.4% v 5.2%), but not Follicular Lymphoma International Prognostic Index score 0 to 1 (4.0% v 3.7%); for patients who failed to achieve event-free survival within 24 months from diagnosis (36.1% v 7.0%), but not for patients who achieved event-free survival within 24 months of diagnosis (6.7% v 5.7%); and for patients with a history of transformed FL (45.9% v 4.7%), but not among patients without (8.1% v 6.2%). Overall, 77 of 140 deaths as a result of lymphoma occurred in patients whose FL transformed after diagnosis. Conclusion Despite the improvement in overall survival in patients with FL in the rituximab era, their leading COD remains lymphoma, especially after disease transformation. Treatment-related mortality also represents a concern, which supports the need for less-toxic therapies.